Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Payables (2019 - 2026)

ADC Therapeutics has reported Payables over the past 8 years, most recently at $5.3 million for Q1 2026.

  • Quarterly results put Payables at $5.3 million for Q1 2026, down 66.04% from a year ago — trailing twelve months through Mar 2026 was $5.3 million (down 66.04% YoY), and the annual figure for FY2025 was $9.2 million, down 49.11%.
  • Payables reached $5.3 million in Q1 2026 per ADCT's latest filing, down from $9.2 million in the prior quarter.
  • Across five years, Payables topped out at $18.0 million in Q4 2024 and bottomed at $5.3 million in Q1 2026.
  • Median Payables over the past 5 years was $11.7 million (2023), compared with a mean of $12.0 million.
  • The largest annual shift saw Payables skyrocketed 102143.38% in 2022 before it crashed 66.04% in 2026.
  • Over 5 years, Payables stood at $12.4 million in 2022, then grew by 26.05% to $15.6 million in 2023, then grew by 15.8% to $18.0 million in 2024, then crashed by 49.11% to $9.2 million in 2025, then crashed by 42.29% to $5.3 million in 2026.
  • Business Quant data shows Payables for ADCT at $5.3 million in Q1 2026, $9.2 million in Q4 2025, and $8.1 million in Q3 2025.